Neuropeptide Y and the calcitonin gene-related peptide attenuate learning impairments induced by MK-801 via a sigma receptor-related mechanism

The European Journal of Neuroscience
P BouchardR Quirion

Abstract

It has been shown recently that low doses of sigma (sigma) receptor ligands like 1,3-di-(2-tolyl)guanidine (DTG), (+)N-allylnormetazocine [(+)SKF 10,047] and (+)pentazocine can antagonize learning impairments induced by dizocilpine (MK-801), a non-competitive antagonist at the NMDA receptor channel. This antagonism has been proposed to involve sigma receptor sites since it is blocked by the administration of purported sigma antagonists such as NE-100 and BMY-14802. It has also been demonstrated that peptides of the neuropeptide Y (NPY) and calcitonin gene-related peptide (CGRP) families modulate, in vivo, sigma labelling and electrophysiological effects in the hippocampal formation. Accordingly, we investigated if NPY- and CGRP-related peptides modulate cognitive processes by interacting with sigma sites in mice. In order to test this hypothesis, a step-down passive avoidance task was used. Interestingly, similarly to various sigma agonists, NPY, peptide YY (PYY) and the Y1 agonist [Leu31Pro34]NPY (but not NPY[13-36], a purported Y2 agonist), as well as hCGRPalpha and the purported CGRP2 agonist [Cys(ACM)2-7]hCGRPalpha (but not CGRP[8-37], a CGRP1 receptor antagonist), significantly attenuated learning impairments induced by MK...Continue Reading

References

Mar 1, 1992·Trends in Pharmacological Sciences·R QuirionD P Taylor
Jul 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·H HerzogL A Selbie
Jan 1, 1992·Pharmacology & Therapeutics·D R Poyner
Jul 1, 1992·Pharmacology, Biochemistry, and Behavior·G ClementiF Drago
Jun 30, 1992·Annals of the New York Academy of Sciences·F B JolicoeurS St-Pierre
Jan 25, 1991·European Journal of Pharmacology·S W Tam, K N Mitchell
Jan 26, 1988·Brain Research·C L CarpenterD A Greenberg
Apr 25, 1989·European Journal of Pharmacology·W D BowenK A McGarry
Oct 18, 1988·European Journal of Pharmacology·B L LargentS H Snyder
Sep 1, 1984·Peptides·D D KrahnJ E Morley
Oct 14, 1994·Brain Research. Developmental Brain Research·J B Hutchins
Dec 1, 1994·Pharmacology, Biochemistry, and Behavior·T MauriceA Privat
Oct 5, 1993·European Journal of Pharmacology·F J RomanJ L Junien
Sep 1, 1995·Physiology & Behavior·A Kovács, G Telegdy
Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·M HannerH Glossmann

❮ Previous
Next ❯

Citations

Jul 22, 2004·Behavioural Brain Research·Cristina C CarvajalRémi Quirion
Nov 13, 2013·Neuropeptides·M J Zaben, W P Gray
Nov 12, 2013·Neuropeptides·Eva BorbélyZsuzsanna Helyes
Nov 11, 1999·Neuroscience Letters·L Bracci-LaudieroC Stenfors
May 25, 2002·The European Journal of Neuroscience·Vân-Ly PhanTangui Maurice
Dec 19, 2009·Proceedings of the National Academy of Sciences of the United States of America·Shang-Yi TsaiTsung-Ping Su
Apr 12, 2008·Molecular and Cellular Endocrinology·William P Gray
Feb 16, 2013·Neuropeptides·Christelle Veyrat-DurebexPierrette Gaudreau
Apr 20, 2005·Journal of Neurochemistry·Owain W HowellWilliam P Gray
Jul 23, 2019·Journal of Psychopharmacology·Johannes Kornhuber, Iulia Zoicas
Aug 14, 2020·Journal of Clinical Medicine·Juho AutioKarl-Heinz Herzig
Jul 16, 2003·The European Journal of Neuroscience·Alexandra TschenettGünther Sperk
Mar 28, 2021·Scientific Reports·Narumi Hashikawa-HobaraNaoya Hashikawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis is a form of of brain inflammation due to antibodies against NMDA receptors. Discover the latest research on anti-NMDA receptor encephalitis here.